• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIXC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Wang Jiawei

    (Last) (First) (Middle)
    C/O 5857 OWENS AVENUE, SUITE 300

    (Street)
    CARLSBAD CA 92008

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/29/2025
    3. Issuer Name and Ticker or Trading Symbol
    AIxCrypto Holdings, Inc. [ AIXC ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Co-Chief Executive Officer
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common stock, Par Value $0.001 1,658 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Series B Convertible Preferred Stock, Par Value $0.001 11/12/2025 (1) Common stock, Par Value $0.001 196 $445.23 D
    Explanation of Responses:
    1. The Series B Shares do not have an expiration date.
    /s/ Jiawei Wang 12/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $AIXC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIXC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIXC
    SEC Filings

    View All

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    3/27/26 4:30:35 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/27/26 4:05:53 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - AIxCrypto Holdings, Inc. (0001460702) (Filer)

    2/17/26 4:05:38 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIXCrypto Co-CEO Jerry Wang Shares Weekly Investor Update: Strategic Real Estate Industry Engagement, Long-Term Infrastructure Direction, and Industry Signals From the Evolving AI Stack

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC) ("AIxC" or the "Company"), a technology company focused on infrastructure for the emerging Embodied AI (EAI) ecosystem, today shared a weekly business update from Co-CEO Jerry Wang highlighting recent industry engagement, the Company's continued long-term infrastructure focus, and broader industry developments relevant to the evolving AI Agent economy. Strategic Industry EngagementThis week, Jerry Wang attended the annual meeting of Pinnacle Real Estate Group in California. The Company believes that engagement with established participants in real-world industries may help inform future infrastructure opportunities rela

    3/24/26 2:00:00 AM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AIxCrypto Acknowledges Conclusion of SEC Investigation with no Enforcement Action Involving majority controlling stockholder, Faraday Future and Reaffirms Strategic Focus

    LOS ANGELES, March 22, 2026 /PRNewswire/ -- AIxCrypto Holdings Inc. (NASDAQ:AIXC) ("AIxCrypto" or the "Company") today acknowledged the public announcement made by its majority controlling stockholder, Faraday Future Intelligent Electric Inc., regarding the conclusion of a previously disclosed U.S. Securities and Exchange Commission (SEC) investigation, which FFAI announced has been resolved with no enforcement action recommended. The Company views this development as an important step toward reducing prior uncertainty associated with the matter. Investors and other interested parties should refer to FFAI's public filings and disclosures for additional information.Significance to AIxCryptoFr

    3/22/26 11:52:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Wang Jiawei claimed ownership of 1,658 shares (SEC Form 3)

    3 - AIxCrypto Holdings, Inc. (0001460702) (Issuer)

    12/5/25 7:46:10 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AIXC
    Leadership Updates

    Live Leadership Updates

    View All

    AIxC Appoints Andrew Grossman As Head of Legal Where He Will Direct the Company's Legal, Compliance, and Governance Strategy

    LOS ANGELES, Dec. 17, 2025 /PRNewswire/ -- AIxCrypto Inc. (NASDAQ:AIXC, ", AIxC", or ", the Company", )) today announced the appointment of Andrew Grossman as Head of Legal. In this role, Andrew will direct the Company's legal, compliance, and governance functions, managing key areas including SEC disclosures, fund and investment compliance, digital asset and Web3 protocol architecture, and major strategic and commercial agreements. Andrew brings extensive experience in securities regulation, digital asset ecosystem architecture, strategic corporate structuring, IP strategy, a

    12/17/25 1:01:00 AM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    $AIXC
    Financials

    Live finance-specific insights

    View All

    AIxCrypto Holdings Reports Full Year 2025 Financial Results; Highlights Transformational Pivot to AI and Blockchain Infrastructure

    LOS ANGELES, March 24, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. (NASDAQ:AIXC, or the ", Company", )), today reported financial results for the fiscal year ended December 31, 2025 — its inaugural annual earnings release following its transformation from a clinical-stage biopharmaceutical company into an AI and blockchain-enabled digital infrastructure company spanning Real World Asset (RWA) tokenization, AI agents and Embodied AI (EAI) blockchain ecosystems, connecting Web2 and Web3. Fiscal year 2025 was principally a period of strategic repositioning, capital formation, and platform development. The Company closed a $41.0 million private placement, rebranded from Qualigen Therapeutics,

    3/24/26 10:01:00 PM ET
    $AIXC
    $FFAI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Auto Manufacturing
    Industrials

    AIxCrypto Announces Fourth Quarter 2025 Earnings Release Date and Conference Call Details

    LOS ANGELES, March 20, 2026 /PRNewswire/ -- AIxCrypto Holdings, Inc. ("AIxC" or the "Company"), a U.S.-Nasdaq listed company dedicated to building an ecosystem that integrates AI and blockchain while bridging Web2 and Web3, today announced that the Company is scheduled to report its fourth quarter financial results for 2025 after market close on Tuesday, March 24, 2026, and will hold an earnings call at 4:30 PM Pacific Time (7:30 PM Eastern Time) that same day. AIxC invites stockholders to submit questions in advance of the upcoming earnings call. Stockholders may email their questions directly to: [email protected]. We welcome your participation and appreciate your continued support.Intereste

    3/20/26 4:15:00 PM ET
    $AIXC
    Biotechnology: Pharmaceutical Preparations
    Health Care